Pfizer raises 2021 COVID-19 vaccine sales forecast to $33.5 billion [Reuters]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Reuters
BioNTech by nearly 29% to $33.5 billion, as nations stock up on doses for the rest of the year. The company also said on Wednesday it could apply for an emergency use authorization for a potential booster dose as early as August, reiterating that a booster shot will likely be needed in the future. The raised sales forecast of the vaccine is based on signed deals for 2.1 billion doses, and the company could increase it if it signs additional contracts. The drugmaker gained a head start in December with the first U.S. emergency authorization of a COVID-19 vaccine, and has since jumped ahead of rivals that have faced manufacturing hurdles. Johnson & Johnson's (JNJ.N) vaccine has also been under scrutiny over safety concerns. J&J last week estimated full-year COVID-19 vaccine sales of $2.5 billion, while Moderna has forecast $19.2 billion. Pfizer said it had shipped 1 billion doses of the vaccine to date since December. The companies have a production target of around 3 billion
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Scholz promises support for pharma sector in Germany as Merck invests [Reuters]Reuters
- Scholz promises support for pharma sector in Germany as Merck invests [Yahoo! Finance]Yahoo! Finance
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024GlobeNewswire
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $107.00 price target on the stock.MarketBeat
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 4/8/24 - Form 6-K
- 4/8/24 - Form 6-K
- 3/25/24 - Form 6-K
- BNTX's page on the SEC website